



IFW A

Attorney Docket No. 59572 (46865)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Jentsch

CONF. NO.: 9926

APPLN SERIAL NO.: 10/622,377

ART UNIT: 1645

FILED: July 18, 2003

EXAMINER: Not yet assigned

FOR: TEST SYSTEM FOR THE DEVELOPMENT OF THERAPEUTIC AGENTS, IN
PARTICULAR ACTIVE COMPOUNDS FOR THE TREATMENT OF
OSTEOPOROSIS

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service with sufficient postage as First Class mail addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on May 14, 2004.

By: Helen Murray Taybi
Helen Murray Taybi

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

05/19/2004 MBERHE 00000136 10622377

01 FC:1806

180.00 DP

II. COPIES

a. ☒ Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

a. ☒ Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in a PCT Search Report.

b. ☐ A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:

c. ☐ The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)
(check one box)

a. ☐ within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1)). No fee or certification is required.

b. ☐ within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2)). No fee or certification is required.

c. ☒ before the mailing date of a first Action on the merits (37 C.F.R. § 1.97(b) (3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below, or, if no certification has been made, charge our deposit account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(c):
(check one box)

a. _____ before the mailing date of a Final Office Action under 37 C.F.R. § 1.113 (See 37 C.F.R. § 1.97(c) (1)) or before the mailing date of a Notice of Allowance under 37 C.F.R. § 1.311 (See 37 C.F.R. § 1.97(c) (2)).

b. ☒ No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).

or

c. _____ See the certification below. No fee is required.

VI. CERTIFICATION UNDER 37 C.F.R. § 1.97(e)
(check only one box)

The undersigned hereby certified that

a. ☒ each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, or

b. _____ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

c. _____ some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VII. THIS IDS IS BEING FILED UNDER 37 C.F.R. §1.97(d)

- a. ☐ after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee, and the requisite Certification, petition, and petition fee are included herein.
- b. ☐ after the mailing date of a Final Office Action under 37 C.F.R. §1.113
- c. ☐ see certificate above
- d. ☒ a fee in the amount of \$180.00 is required by 37 CFR §1.17(p)
- e. ☐ applicant hereby petitions that this Information Disclosure Statement is considered in accordance with 37 C.F.R. §1.97(d).


☒ Enclosed is a check in the amount of \$180.00 for the above-indicated fee. Should any further fee be associated with the submission of this Information Disclosure Statement, the Commissioner is authorized to charge our Deposit Account No. 04-1105.

☐ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition, if necessary) and charge the appropriate fee to Deposit Account No. 04-1105.


Respectfully submitted,

Date: May 14, 2004


Greg B. Butler
Registration No. 34,558
EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, Massachusetts 02205
Telephone: (617) 439-4444

Customer No.: 21874

FORM PTO-1449


**INFORMATION DISCLOSURE
STATEMENT**
DOCKET NO:

59572 (46865)

SERIAL NO.:

10/622,377

APPLICANT(S): Jentsch**FILING DATE:**

July 18, 2003

GROUP NO.:

1645

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

1	C1	Hartinger, et al., "An Anion Binding Site That Regulates the Glutamate Transporter of Synaptic Vesicles," Journal of Biological Chemistry, Vol. 268, No. 31, pp. 23122-23127, 1993.
2	C2	Ratcliff, et al., "Production of a Severe Cystic Fibrosis Mutation in Mice by Gene Targeting, Nature Genetics," Vol. 4, pp. 35-41, 1993.
3	C3	Vincent, et al., "Antisense Suppression of Potassium Channel Expression Demonstrates Its Role in Maturation of the Action Potential, Journal of Neuroscience," Vol. 20, pp. 6087-6094, 2000.
4	C4	Wang, et al., "The Role of CIC-3 in Volume-Activated Chloride Currents and Volume Regulation in Bovine Epithelial Cells Demonstrated by Antisense Inhibition," Journal of Physiology, Vol. 524.1, pp. 63-75, 2000.
5	C5	Tottene, et al., " α_{1E} Subunits Form the Pore of Three Cerebellar R-Type Calcium Channels with Different Pharmacological and Permeation Properties," Journal of Neuroscience, Vol. 20, pp. 171-178, 2000.
6	C6	Clarke, et al., "Defective Epithelial Chloride Transport in a Gene-Targeted Mouse Model of Cystic Fibrosis," Science, Vol. 257, pp. 1125-1128, 1992.
7	C7	Miesenböck, et al., "Visualizing Secretion and Synaptic Transmission with pH-Sensitive Green Fluorescent Proteins," Nature, Vol. 394, pp. 192-195, 1998.
8	C8	Maycox, et al., "Glutamate Uptake by Brain Synaptic Vesicles," Journal of Biological Chemistry, Vol. 263, pp. 15423-15428, 1988.
9	C9	Piwon, et al., "CIC-5 Cl-Channel Disruption Impairs Endocytosis in a Mouse Model for Dent's Disease," Nature, Vol. 408, pp. 369-373, 2000.
10	C10	Schaertl, et al., "A Novel and Robust Homogeneous Fluorescence-Based Assay Using Nanoparticles for Pharmaceutical Screening and Diagnosis," Journal of Biomolecular Screening, Vol. 5, pp. 227-237, 2000.
11	C11	Yamamoto, et al., "Characterization of Renal Chloride Channel (CLCN5) Mutations in Dent's Disease," Journal of the American Society of Nephrology, Vol. 11, pp. 1460-1468, 2000.
12	C12	Sun, et al., "CD38/ADP-Ribosyl Cyclase: A New Role in the Regulation of Osteoclastic Bone Resorption," Journal of Cell Biology, Vol. 146, pp. 1161-1171, 1999.
13	C13	Kask, et al., "Fluorescence-Intensity Distribution Analysis and Its Application in Biomolecular Detection Technology," PNAS, Vol. 96, pp. 13756-13761, 1999.
14	C14	Kawasaki, et al., "Cloning and Expression of a Protein Kinase C-Regulated Chloride Channel Abundantly Expressed in Rat Brain Neuronal Cells," Neuron, Vol. 12, pp. 597-604, 1994.
15	C15	Thomas-Reetz, et al., "A γ -Aminobutyric Acid Transporter Driven by a Proton Pump is Present in Synaptic-Like Microvesicles of Pancreatic β -Cells," Proceedings of the National Academy of Sciences USA, Vol. 90, pp. 5317-5321, 1993.
16	C16	Overly, et al., "Quantitative Measurement of Intraorganelle pH in the Endosomal-Lysosomal Pathway in Neurons by Using Ratiometric Imaging with Pyranine," Proceedings of the National Academy of Sciences USA, Vol. 92, pp. 3156-3160, 1995.
17	C17	Xia, et al., "Localization of Rat Cathepsin K in Osteoclasts and Resorption Pits: Inhibition of Bone Resorption and Cathepsin K-Activity by Peptidyl Vinyl Sulfones," Biological Chemistry, Vol. 380, pp. 679-687, 1999.
18	C18	Yeager, et al., "Constructing Immortalized Human Cell Lines," Current Opinion in Biotechnology, Vol. 10, pp. 465-469, 1999.
19	C19	Palo, et al., "Fluorescence Intensity Multiple Distributions Analysis: Concurrent Determination of Diffusion Times and Molecular Brightness," Biophysical Journal, Vol. 79, pp. 2858-2866, 2000.
20	C20	Diwu, et al., "A Novel Acidotropic pH Indicator and Its Potential Application in Labeling Acidic Organelles of Live Cells," Chemistry & Biology, Vol. 6, pp. 411-418, 1999.
21	C21	Reimer, et al., "Vesicular Neurotransmitter Transport and the Presynaptic Regulation of Quantal Size," Current Opinion in Neurobiology, Vol. 8, pp. 405-412, 1998.
22	C22	Gasnier, "The Loading of Neurotransmitters Into Synaptic Vesicles," Biochimie, Vol. 82, pp. 327-337, 2000.
23	C23	Karlsson, "Real-Time Competitive Kinetic Analysis of Interactions Between Low-Molecular Weight Ligands in Solution and Surface-Immobilized Receptors," Analytical Biochemistry, Vol. 221, pp. 142-151, 1994.

FORM PTO-1449		DOCKET NO: 59572 (46865)	SERIAL NO.: 10/622,377
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Jentsch	
		FILING DATE: July 18, 2003	GROUP NO.: 1645
24	C24	Frostell-Karlsson, et al., "Biosensor Analysis of the Interaction Between Immobilized Human Serum Albumin and Drug Compounds for Prediction of Human Serum Albumin Binding Levels," Journal of Medical Chemistry, Vol. 43, pp. 1986-1992, 2000.	
25	C25	Parmjit, et al., "Direct Derivation of Conditionally Immortal Cell Lines from an H-2K ^b -tsA58 Transgenic Mouse," Proceedings of the National Academy of Sciences USA, Vol. 88, pp. 5096-5100, 1991.	
26	C26	Llopis, et al., "Measurement of Cytosolic, Mitochondrial, and Golgi pH in Single Living Cells with Green Fluorescent Proteins," Proceedings of the National Academy of Sciences USA, Vol. 95, pp. 6803-6808, 1998.	
27	C27	Whitehead, et al., "Establishment of Conditionally Immortalized Epithelial Cell Lines from Both Colon and Small Intestine of Adult H-2K ^b -tsA58 Transgenic Mice," Proceedings of the National Academy of Sciences USA, Vol. 90, pp. 587-591, 1993.	
28	C28	Markgren, et al., "Kinetic Analysis of the Interaction Between HIV-1 Protease and Inhibitors Using Optical Biosensor Technology," Analytical Biochemistry, Vol. 279, pp. 71-78, 2000.	
29	C29	Williams, "Biotechnology Match Making: Screening Orphan Ligands and Receptors," Current Opinion in Biotechnology, Vol. 11, p. 42-46, 2000.	
30	C30	Beerheide, et al., "Potential Drugs Against Cervical Cancer: Zinc-Ejecting Inhibitors of the Human Papillomavirus Type 16 E6 Oncoprotein," Journal of the National Cancer Institute, Vol. 91, pp. 1211-1220, 1999.	
31	C31	Jen, et al., "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," Stem Cells, Vol. 18, pp. 307-319, 2000.	
32	C32	Deckert, et al., "Development and Validation of an IL-6 Immuno-Receptor Assay Based on Surface Plasmon Resonance," Journal of Pharmaceutical and Biomedical Analysis, Vol. 23, pp. 403-412, 2000.	
33	C33	Shioi, et al., "Glutamate Uptake Into Synaptic Vesicles of Bovine Cerebral Cortex and Electrochemical Potential Difference of Proton Across the Membrane," Biochemistry Journal, Vol. 258, pp. 499-504, 1989.	
34	C34	Kubisch, et al., CIC-1 Chloride Channel Mutations in Myotonia Congenita: Variable Penetrance of Mutations Shifting the Voltage Dependence," Human Molecular Genetics, Vol. 7, pp. 1753-1760, 1998.	
35	C35	Lorenz, et al., "Genomic Organization of the Human Muscle Chloride Channel CIC-1 and Analysis of Novel Mutations Leading to Becker-Type Myotonia," Human Molecular Genetics, Vol. 3, pp. 941-946, 1994.	
36	C36	Tycko, et al., "Rapid Acidification of Endocytic Vesicles Containing α_2 -Macroglobulin," Cell, Vol. 28, pp. 643-651, 1982.	
37	C37	Boyde, et al., "Resorption of Dentine by Isolated Osteoclasts <i>in vitro</i> ," British Dental Journal, Vol. 156, pp. 216-220, 1984.	
38	C38	Chapman, et al., "Retrieval of TGN Proteins From the Cell Surface Requires Endosomal Acidification," The EMBO Journal, Vol. 13, pp. 2305-2312, 1994.	
39	C39	Katakura, et al., "Immortalization by Gene Transfection," Methods in Cell Biology, Vol. 57, pp 69-91, 1998.	
40	C40	Hell, et al., "Uptake of GABA By Rat Brain Synaptic Vesicles Isolated By a New Procedure," The EMBO Journal, Vol. 7, pp. 3023-3029, 1988.	
41	C41	Giovanna, et al., "Synergy Between <i>Apc</i> ^{min} and an Activated <i>ras</i> Mutation Is Sufficient to Induce Colon Carcinomas," Molecular and Cellular Biology, Vol. 16, pp. 884-891, 1996.	
42	C42	Nako, et al., "Inhibition by Antisense Oligonucleotides of Plasma Membrane Ca ²⁺ ATPase in Vascular Endothelial Cells," European Journal of Pharmacology, Vol. 387, pp. 273-277, 2000.	
43	C43	Dorin, et al., "Cystic Fibrosis in the Mouse by Targeted Insertional Mutagenesis," Nature, Vol. 359, pp. 211-215, 1992.	
44	C44	Johnson, et al., "Endosome Acidification and Receptor Trafficking: Bafilomycin A ₁ Slows Receptor Externalization by a Mechanism Involving the Receptor's Internalization Motif," Molecular Biology of the Cell, Vol. 4, pp. 1251-1266, 1993.	
45	C45	Wu, et al., "[39] Studying Organelle Physiology with Fusion Protein-Targeted Avidin and Fluorescent Biotic Conjugates," Methods in Enzymology, Vol. 327, pp. 546-564, 2000.	
46	C46	Van Noorden, et al., "Localization of Cathepsin B Activity in Fibroblasts and Chondrocytes by Continuous Monitoring of the Formation of Final Fluorescent Reaction Product Using 5-Nitrosalicylaldehyde," Histochemical Journal, Vol. 19, pp. 483-487, 1987.	

FORM PTO-1449		DOCKET NO: 59572 (46865)	SERIAL NO.: 10/622,377
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Jentsch	
		FILING DATE: July 18, 2003	GROUP NO.: 1645
47	C47	Mellman, "The Importance of Being Acid: The Role of Acidification in Intracellular Membrane Traffic," <i>Journal Experimental Biology</i> , Vol. 172, pp. 39-45, 1992.	
48	C48	Presley, et al., "Bafilomycin A ₁ Treatment Retards Transferrin Receptor Recycling More Than Bulk Membrane Recycling," <i>Journal of Biological Chemistry</i> , Vol. 272, pp. 13929-13936, 1997.	
49	C49	Tabb, et al., "Glutamate Transport into Synaptic Vesicles," <i>Journal of Biological Chemistry</i> , Vol. 267, pp. 15412-15418, 1992.	
50	C50	Leconte, et al., "Impairment of Rod cGMP-Gated Channel α -Subunit Expression Leads to Photoreceptor and Bipolar Cell Degeneration," <i>Investigative Ophthalmology & Visual Science</i> , Vol. 41, pp. 917-926, 2000.	
51	C51	Lloyd, et al., "Characterisation of Renal Chloride Channel, CLCN5, Mutations in Hypercalciuric Nephrolithiasis (kidney stones) Disorders," <i>Human Molecular Genetics</i> , Vol. 6, pp. 1233-1239, 1997.	
52	C52	Brenner, et al., "Vasoregulation by the β 1 Subunit of the Calcium-Activated Potassium Channel," <i>Nature</i> , Vol. 407, pp. 870-876, 2000.	
53	C53	Brandt, et al., "CIC-6 and CIC-7 Are Two Novel Broadly Expressed Members of the CLC Chloride Channel Family," <i>FEBS Letters</i> , Vol. 377, pp. 15-20, 1995.	
54	C54	Inoue, et al., "Visualization of Acidic Compartments in Cultured Osteoclasts by Use of an Acidotrophic Amine as a Marker for Low pH," <i>Cell Tissue Research</i> , Vol. 298, pp. 527-537, 1999.	
55	C55	Piwon, et al., "CIC-5 Cl-Channel Disruption Impairs Endocytosis in a Mouse Model for Dent's Disease," <i>Nature</i> , Vol. 408, pp. 369-373, 2000.	
56	C56	Pusch, et al., "Mutations in Dominant Human Myotonia Congenita Drastically Alter the Voltage Dependence of the CIC-1 Chloride Channel," <i>Neuron</i> , Vol. 15, pp. 1455-1463, 1995.	
57	C57	Llyod, et al., "A Common Molecular Basis for Three Inherited Kidney Stone Diseases," <i>Nature</i> , Vol. 39, pp. 445-449, 1996.	
58	C58	Meyer-Kleine, et al., "Spectrum of Mutations in the Major Human Skeletal Muscle Chloride Channel Gene (CLCN1) Leading to Myotonia," <i>American Journal of Human Genetics</i> , Vol. 57, pp. 1325-1334, 1995.	
59	C59	Baron, et al., "Cell-Mediated Extracellular Acidification and Bone Resorption: Evidence for a Low pH in Resorbing Lacunae and Localization of a 100-kD Lysosomal Membrane Protein at the Osteoclast Ruffled Border," <i>Journal of Cell Biology</i> , Vol. 101, pp. 2210-2222, 1985.	
60	C60	Demaurex, et al., "Mechanism of Acification of the <i>trans</i> -Golgi Network (TGN) <i>IN SITU</i> MEASUREMENTS OF pH USING RETREIVAL OF TGN38 AND FURIN FROM THE CELL SURFACE," <i>Journal of Biological Chemistry</i> , Vol. 273, pp. 2044-2051, 1997.	
61	C61	Igarashi, et al., "Functional Characterization of Renal Chloride Channel, CLCN5, Mutations Associated with Dent's Japan Disease," <i>Kidney International</i> , Vol. 54, pp. 1850-1856, 1998.	
62	C62	Failke, "Molecular Mechanisms of Ion Conduction in CIC-Type Chloride Channels: Lessons from Disease-Causing Mutations," <i>Kidney International</i> , Vol. 57, pp. 780-786, 2000.	
63	C63	Kneen, et al., "Green Fluorescent Protein as a Noninvasive Intracellular pH Indicator," <i>Biophysical Journal</i> , Vol. 74, pp. 1591-1599, 1998.	
64	C64	Zen, et al., "Second Messengers Regulate Endosomal Acidification in Swiss 3T3 Fibroblasts," <i>Journal of Cell Biology</i> , Vol. 119, pp. 99-110, 1992.	
65	C65	Lewalle, et al., "Inhibition of P210 Expression in Chronic Myeloid Leukaemia: Oligonucleotides and/or Transduced Antisense Sequences," <i>Leukemia and Lymphoma</i> , Vol. 11, pp. 139-143, 1993.	
66	C66	Marschall, et al., "Inhibition of Gene Expression with Ribozymes," <i>Cellular and Molecular Neurobiology</i> , Vol. 14, pp. 523-538, 1994.	
67	C67	Borsani, et al., "Characterization of Human and Murine Gene (CLCN3) Sharing Similarities to Voltage-Gated Chloride Channels and to a Yeast Integral Membrane Protein," <i>Genomics</i> , Vol. 27, pp. 131-141, 1995.	
68	C68	Siegel, et al., "A Genetically Encoded Optical Probe of Membrane Voltage," <i>Neuron</i> , Vol. 19, pp. 735-741, 1997.	
69	C69	Presley, et al., "The <i>End2</i> Mutation in CHO Cells Slows the Exit of Transferrin Receptors from the Recycling Compartment but Bulk Membrane Recycling Is Unaffected," <i>Journal of Cell Biology</i> , Vol. 122, pp. 1231-1241, 1993.	
70	C70	Steinmeyer, et al., "Multimeric Structure of CIC-1 Chloride Channel Revealed by Mutations in Dominant Myotonia Congenita (Thomsen)," <i>EMBO Journal</i> , Vol. 13, pp. 737-743, 1994.	

FORM PTO-1449			DOCKET NO: 59572 (46865)		SERIAL NO.: 10/622,377	
INFORMATION DISCLOSURE STATEMENT			APPLICANT(S): Jentsch			
			FILING DATE: July 18, 2003		GROUP NO.: 1645	
71	C71	Ratcliff, et al., "Disruption of the Cystic Fibrosis Transmembrane Conductance Regulator Gene in Embryonic Stem Cells by Gene Targeting," Transgenic Research, Vol. 1, pp. 177-181, 1992.				
72	C72	Schwappach, et al., "Golgi Localization and Functionally Important Domains in the NH ₂ and COOH Terminus of the Yeast CLC Putative Chloride Channel Geflp," Journal of Biological Chemistry, Vol. 273, pp. 15110-15118, 1998.				
73	C73	Liu, et al., "Ribozyme Ablation Demonstrates That the Cardiac Subtype of the Voltage-Sensitive Calcium Channel Is the Molecular Transducer of 1,25-Dihydroxyvitamin D ₃ -Stimulated Calcium Influx in Osteoblastic Cells," Journal of Biological Chemistry, Vol. 275, pp. 8711-8718, 2000.				
74	C74	Hell, et al., "Energy Dependence and Functional Reconstitution of the γ -Aminobutyric Acid Carrier from Synaptic Vesicles," Journal of Biological Chemistry, Vol. 265, pp. 2111-2117, 1990.				
75	C75	Matsumura, et al., "Overt Nephrogenic Diabetes Insipidus in Mice Lacking the CLC-K1 Chloride Channel," Nature Genetics, Vol. 21, pp. 95-98, 1999.				
76	C76	Clague, et al., "Vacuolar ATPase Activity Is Required for Endosomal Carrier Vesicle Formation," Journal of Biological Chemistry, Vol. 269, pp. 21-24, 1994.				
77	C77	Laitala-Leinonen, et al., "Inhibition of Intravacuolar Acidification by Antisense RNA Decreases Osteoclast Differentiation and Bone Resorption In Vitro," Journal of Cell Science, Vol. 112, pp. 3657-3666, 1999.				
78	C78	Ilvesaro, et al., "Bone-Resorbing Osteoclasts Contain Gap-Junctional Connexin-43," Journal of Bone and Mineral Research, Vol. 15, pp. 919-926, 2000.				
79	C79	Udagawa, et al., "Osteoblasts/Stromal Cells Stimulate Osteoclast Activation Through Expression of Osteoclast Differentiation Factor/RANKL but Not Macrophage Colony-Stimulating Factor," Bone, Vol. 25, pp. 517-523, 1999.				
80	C80	Lloyd, et al., "Idiopathic Low Molecular Weight Proteinuria Associated with Hypercalciuric Nephrocalcinosis in Japanese Children Is Due to Mutations of the Renal Chloride Channel (CLCN5), Journal of Clinical Investigation, Vol. 99, pp. 967-974, 1997.				
81	C81	Lee, et al., "Targeted Disruption of the <i>Kulqt1</i> Gene Causes Deafness and Gastric Hyperplasia in Mice," Journal of Clinical Investigation, Vol. 106, pp. 1447-1455, 2000.				
82	C82	Montrose-Rafizadeh, et al., "Gene Targeting of a CFTR Allele in HT29 Human Epithelial Cells," Journal of Cellular Physiology, Vol. 170, pp. 299-308, 1997.				
83	C83	Redey, et al., "Osteoclast Adhesion and Activity on Synthetic Hydroxyapatite, Carbonated Hydroxyapatite, and Natural Calcium Carbonate: Relationship to Surface Energies," Journal of Biomedical Research, Vol. 45, pp. 140-147, 1999.				
84	C84	Brussaard, "Antisense Oligonucleotides Induce Functional Deletion of Ligand Gated Ion Channels in Cultured Neurons and Brain Explants," Journal of Neuroscience Methods, Vol. 71, pp. 55-64, 1997.				
85	C85	Friedrich, et al., "Mutational Analysis Demonstrates That CIC-4 and CIC-5 Directly Mediate Plasma Membrane Currents," Journal of Biological Chemistry, Vol. 27, pp. 896-902, 1999.				
86	C86	Gronemeier, et al., "Nonsense and Missense Mutations in the Muscular Chloride Channel Gene <i>Clc-1</i> of Myotonic Mice," Journal of Biological Chemistry, Vol. 269, pp. 5963-5967, 1994.				
87	C87	Schapiro, et al., "Determinants of the pH of the Golgi Complex," Journal of Biological Chemistry, Vol. 275, pp. 21025-21032, 2000.				
88	C88	Schmidt-Rose, et al., "Reconstitution of Functional Voltage-Gated Chloride Channels From Complementary Fragments of CLC-1," Journal of Biological Chemistry, Vol. 272, pp. 20515-20521, 1997.				
89	C89	Sterrer, et al., "Fluorescence Correlation Spectroscopy (FCS) - A Highly Sensitive Method to Analyze Drug/Target Interactions," Journal of Receptor & Signal Transduction Research, Vol. 17, pp. 511-520, 1997.				
90	C90	Kornak, et al., "Complete Genomic Structure of the CLCN6 and CLCN7 Putative Chloride Channel Genes," Biochimica et Biophysica Acta, Vol. 1447, pp. 100-106, 1999.				
91	C91	Chambers, et al., "Resorption of Bone by Isolated Rabbit Osteoclasts," Journal of Cell Science, Vol. 66, pp. 383-399, 1984.				
92	C92	Vandewalle, "Immortalized Kidney Cells Derived from Transgenic Mice Harboring L-Type Pyruvate Kinase and Vimentin Promoters," Experimental Nephrology, Vol. 7, pp. 386-393, 1999.				
93	C93	Gökhan, et al., "Generation and Regulation of Developing Immortalized Neural Cell Lines," Methods, Vol. 16, pp. 345-358, 1998.				

FORM PTO-1449		DOCKET NO: 59572 (46865)	SERIAL NO.: 10/622,377
INFORMATION DISCLOSURE STATEMENT		APPLICANT(S): Jentsch	
		FILING DATE: July 18, 2003	GROUP NO.: 1645
94	C94	Okazaki, et al., "Thiazolidinediones Inhibit Osteoclast-Like Cell Formation and Bone Resorption <i>in Vitro</i> ," Endocrinology, Vol. 140, pp. 5060-5065, 1999.	
95	C95	Luyckx, et al., "Diet-Dependent Hypercalciuria in Transgenic Mice with Reduced CLC5 Chloride Channel Expression," PNAS, Vol. 96, pp. 12174-12179, 1999.	
EXAMINER:			DATE: